Table 3.
SHRs and AERs of any cerebrovascular event, cerebral haemorrhage (ICD10: I61-I62), Cerebral infarction (ICD10:I63, I65-66) or other cerebrovascular event (ICD10:I64, I67-I68) among CNS tumours survivors by tumour diagnosis, sex, age at diagnosis, decade of diagnosis and attained age
| Any CV Event (ICD10: I60-I68) | Cerebral Haemorrhage (ICD10: I61-I62) | Cerebral infarction (ICD10: I63, I66-67) | Other CV Event (ICD10: I64, I67-I68) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| O | SHR (95% CI) | AER (95% CI) | 1 O | SHR (95% CI) | AER (95% CI) | 1 O | SHR (95% CI) | AER (95% CI) | O | SHR (95% CI) | AER (95% CI) | |
| All CNS tumours | 616 | 4.6 (4.3,5.0) | 33.9 (30.5,37.4) | 183 | 8.3 (7.2,9.6) | 11.2 (9.3,13.0) | 256 | 4.4 (3.9,5.0) | 13.8 (11.6,16.0) | 268 | 5.1 (4.5,5.8) | 15.1 (12.8,17.3) |
| CNS tumour type | ||||||||||||
| Glial Tumour | 254 | 10.8 (9.5,12.3) | 72.3 (62.5,82.1) | 108 | 26.2 (21.5,31.6) | 32.1 (25.8,38.3) | 94 | 9.3 (7.5,11.4) | 25.9 (20.1,31.8) | 89 | 10.1 (8.1,12.4) | 24.8 (19.1,30.5) |
| Embryonal Tumour | 21 | 12.9 (8.0,19.7) | 78.0 (41.9,114.2) | * | * | * | 13 | 18.8 (10.0,32.1) | 49.1 (20.9,77.3) | 12 | 20.2 (10.4,35.3) | 45.6 (18.5,72.7) |
| Craniopharyngioma | 24 | 6.0 (3.8,8.9) | 43.9 (22.8,65.0) | 5 | 7.3 (2.4,17.0) | 9.3 (-0.2,18.7) | 12 | 6.8 (3.5,11.9) | 22.1 (7.5,36.8) | 10 | 6.5 (3.1,12.0) | 18.5 (5.0,32.0) |
| Other Pituitary Tumours | 115 | 3.4 (2.8,4.0) | 21.7 (16.1,27.4) | 12 | 2.1 (1.1,3.7) | 1.7 (-0.1,3.5) | 55 | 3.8 (2.8,4.9) | 10.8 (6.9,14.7) | 61 | 4.6 (3.5,5.9) | 12.8 (8.7,16.9) |
| Meningioma | 52 | 2.1 (1.5,2.7) | 12.9 (6.1,19.6) | 13 | 3.4 (1.8,5.7) | 4.3 (1.0,7.7) | 24 | 2.2 (1.4,3.3) | 6.2 (1.7,10.8) | 20 | 1.9 (1.2,3.0) | 4.6 (0.4,8.7) |
| Ependymoma | 30 | 4.9 (3.3,7.0) | 35.5 (19.5,51.5) | 6 | 5.7 (2.1,12.4) | 7.3 (0.2,14.3) | 17 | 6.1 (3.6,9.8) | 21.0 (9.1,32.9) | 13 | 5.5 (3.0,9.5) | 15.7 (5.3,26.2) |
| Germ Cell Intracranial | 9 | 8.1 (3.7,15.3) | 40.5 (10.3,70.8) | * | * | * | 5 | 10.5 (3.4,24.6) | 23.1 (0.7,45.5) | 5 | 12.6 (4.1,29.5) | 23.4 (1.1,45.7) |
| Other specified | 56 | 2.0 (1.5,2.6) | 10.3 (4.8,15.7) | 22 | 4.8 (3.0,7.3) | 6.5 (3.1,9.9) | 19 | 1.5 (0.9,2.4) | 2.4 (-0.8,5.6) | 26 | 2.3 (1.5,3.4) | 5.5 (1.8,9.2) |
| Other Unspecified | 55 | 5.9 (4.4,7.7) | 47.2 (32.2,62.2) | 14 | 9.0 (4.9,15.0) | 12.6 (5.2,20.1) | 17 | 4.1 (2.4,6.5) | 13.0 (4.8,21.2) | 32 | 8.7 (5.9,12.2) | 28.9 (17.6,40.3) |
| P-heterogeneity | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | ||||
| Sex Male | 339 | 4.8 (4.3,5.3) | 40.8 (35.3,46.3) | 105 | 8.5 (6.9,10.2) | 13.9 (10.9,16.9) | 140 | 4.2 (3.5,4.9) | 16.0 (12.5,19.5) | 153 | 5.8 (4.9,6.8) | 19.1 (15.4,22.7) |
| Female | 277 | 4.4 (3.9,4.9) | 28.0 (23.8,32.3) | 78 | 8.1 (6.4,10.2) | 8.9 (6.6,11.1) | 116 | 4.8 (3.9,5.7) | 11.9 (9.2,14.7) | 115 | 4.4 (3.7,5.3) | 11.6 (8.9,14.3) |
| P-heterogeneity | 0.272 | <0.001 | 0.805 | 0.006 | 0.280 | 0.066 | 0.028 | 0.001 | ||||
| Age at FPN Diagnosis (years) | ||||||||||||
| 15-19 | 79 | 12.7 (10.1,15.9) | 37.7 (28.7,46.8) | 28 | 21.8 (14.5,31.5) | 13.7 (8.4,19.0) | 32 | 13.6 (9.3,19.2) | 15.2 (9.5,20.9) | 30 | 14.8 (10.0,21.1) | 14.4 (8.9,19.9) |
| 20-24 | 67 | 6.3 (4.9,8.0) | 25.5 (18.3,32.8) | 17 | 8.5 (5.0,13.7) | 6.7 (3.1,10.4) | 28 | 6.7 (4.4,9.6) | 10.7 (6.1,15.4) | 28 | 7.5 (5.0,10.9) | 10.9 (6.3,15.6) |
| 25-29 | 113 | 5.7 (4.7,6.8) | 33.1 (25.7,40.5) | 34 | 9.7 (6.7,13.6) | 10.7 (6.7,14.8) | 48 | 5.8 (4.3,7.7) | 14.0 (9.2,18.8) | 49 | 6.7 (5.0,8.9) | 14.7 (9.9,19.5) |
| 30-34 | 146 | 4.1 (3.4,4.8) | 32.5 (25.5,39.5) | 53 | 9.1 (6.8,11.9) | 13.8 (9.6,17.9) | 52 | 3.3 (2.5,4.4) | 10.7 (6.5,14.8) | 56 | 4.0 (3.1,5.2) | 12.3 (8.1,16.6) |
| 35-39 | 211 | 3.5 (3.0,4.0) | 38.7 (31.3,46.0) | 51 | 5.4 (4.0,7.1) | 10.5 (7.0,14.1) | 96 | 3.5 (2.8,4.2) | 17.4 (12.5,22.3) | 105 | 4.1 (3.4,5.0) | 20.3 (15.2,25.4) |
| P-trend | <0.001 | 0.393 | <0.001 | 0.791 | <0.001 | 0.555 | <0.001 | 0.111 | ||||
| Decade of FPN Diagnosis | ||||||||||||
| 1971-1979 | 142 | 3.3 (2.8,3.9) | 53.4 (40.9,66.0) | 26 | 4.2 (2.7,6.1) | 10.4 (5.1,15.6) | 59 | 3.0 (2.3,3.8) | 20.6 (12.6,28.5) | 83 | 4.5 (3.6,5.5) | 34.2 (24.7,43.7) |
| 1980-1989 | 234 | 4.6 (4.1,5.3) | 38.5 (32.2,44.8) | 49 | 5.8 (4.3,7.7) | 8.4 (5.6,11.2) | 107 | 4.9 (4.0,5.9) | 17.7 (13.5,21.9) | 115 | 5.9 (4.9,7.1) | 19.8 (15.5,24.2) |
| 1990-1999 | 179 | 5.4 (4.6,6.2) | 24.8 (20.3,29.2) | 72 | 11.9 (9.3,15.0) | 11.1 (8.3,13.9) | 71 | 5.4 (4.2,6.8) | 9.8 (7.0,12.6) | 57 | 4.9 (3.7,6.3) | 7.7 (5.2,10.2) |
| 2000-2006 | 61 | 8.5 (6.5,10.9) | 31.5 (22.5,40.5) | 36 | 26.5 (18.6,36.7) | 20.3 (13.4,27.1) | 19 | 6.3 (3.8,9.9) | 9.3 (4.4,14.3) | 13 | 5.4 (2.9,9.2) | 6.2 (2.1,10.3) |
| P-trend | <0.001 | <0.001 | <0.001 | 0.005 | <0.001 | <0.001 | 0.451 | <0.001 | ||||
| Attained Age (years) | ||||||||||||
| 20-44 | 200 | 8.4 (7.3,9.7) | 24.6 (20.7,28.5) | 87 | 17.9 (14.4,22.1) | 11.4 (8.9,14.0) | 65 | 8.2 (6.3,10.4) | 7.9 (5.7,10.1) | 50 | 6.6 (4.9,8.7) | 5.9 (4.0,7.8) |
| 44-49 | 118 | 5.5 (4.6,6.6) | 36.0 (28.1,43.9) | 40 | 10.5 (7.5,14.4) | 13.4 (8.8,17.9) | 52 | 6.4 (4.8,8.5) | 16.2 (11.0,21.5) | 54 | 7.2 (5.4,9.5) | 17.2 (11.9,22.5) |
| 50-54 | 104 | 4.4 (3.6,5.4) | 41.8 (31.4,52.1) | 24 | 6.1 (3.9,9.1) | 10.2 (5.3,15.1) | 40 | 4.1 (2.9,5.5) | 15.5 (9.1,21.8) | 58 | 6.6 (5.0,8.5) | 25.2 (17.6,32.9) |
| 54-59 | 88 | 3.9 (3.1,4.8) | 51.3 (36.8,65.7) | 15 | 4.2 (2.4,7.0) | 8.8 (3.0,14.6) | 46 | 4.4 (3.2,5.9) | 27.5 (17.2,37.8) | 44 | 4.9 (3.6,6.6) | 27.1 (17.1,37.2) |
| 60+ | 106 | 2.5 (2.1,3.0) | 54.6 (37.3,71.9) | 17 | 2.9 (1.7,4.6) | 9.1 (2.5,15.8) | 53 | 2.4 (1.8,3.2) | 26.0 (14.1,37.9) | 62 | 3.2 (2.4,4.1) | 35.7 (22.7,48.6) |
| P-trend | <0.001 | <0.001 | <0.001 | 0.441 | <0.001 | <0.001 | <0.001 | <0.001 | ||||
Abbreviations: CV=cerebrovascular; ICD= International classification of disease; O= observed; SHR=standardised hospitalisation ratio; AER=absolute excess risk; CI=confidence interval; FPN=first primary neoplasms; CNS=central nervous system; NHL=non-Hodgkin lymphoma; STS=soft-tissue sarcoma; GU=genitourinary.
*
Omitted from table due to few events (less than 5 observed).